Αρχική World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus... World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC Από Ogkologos - 29 Σεπτεμβρίου, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR New targeted treatment for early breast cancer could reduce risk of... 21 Ιουλίου, 2022 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan 25 Οκτωβρίου, 2021 Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... 11 Δεκεμβρίου, 2019 What People in Asian American and Pacific Islander Communities Should Know... 5 Σεπτεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... Children’s cancer charities team up for tomorrow’s treatments Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy...